Erythropoietin <i>N</i>-glycosylation of Therapeutic Formulations Quantified and Characterized: An Interlab Comparability Study of High-Throughput Methods
Recombinant human erythropoietin (EPO) is a biopharmaceutical frequently used in the treatment of anemia. It is a heavily glycosylated protein with a diverse and complex glycome. EPO <i>N</i>-glycosylation influences important pharmacological parameters, prominently serum half-life. Ther...
Main Authors: | Róisín O’Flaherty, Manuela Amez Martín, Richard A. Gardner, Patrick M. Jennings, Pauline M. Rudd, Daniel I. R. Spencer, David Falck |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-01-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/14/1/125 |
Similar Items
-
The Role of Erythropoietin in Preventing Anemia in the Premature Neonate
by: Oana Cristina Costescu, et al.
Published: (2023-11-01) -
Erythropoietin for the treatment of anemia in patients with hematologic disorders
by: R. A. Podgurskaya, et al.
Published: (2022-11-01) -
Detection of antibodies to erythropoietin-based drugs: is it possible to create the universal test system?
by: A. M. Kudryashova, et al.
Published: (2021-06-01) -
Erythropoietin Receptor (EPOR) Signaling in the Osteoclast Lineage Contributes to EPO-Induced Bone Loss in Mice
by: Zamzam Awida, et al.
Published: (2022-10-01) -
Successful treatment of severe anemia using erythropoietin in a Jehovah Witness with non-Hodgkin lymphoma
by: Alexandra Agapidou, et al.
Published: (2014-12-01)